Best Infectious Diseases Companies in New York City, United States
The 38 best Infectious Diseases companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 75 mo ago | 395 | Kerry Blanchard CEO | Public | — | — |
| 2 | SIGA Technologies Developer of anti-infective therapeutics for bio-warfare threats | $248M | 117 mo ago | 39 | — | Public | 279 patents Antiviral small‑molecule synthesis and oral/IV formulation of Tecovirimat. | — |
| 3 | Elion Therapeutics Developer of therapeutics for invasive fungal infections | $81M | 26 mo ago | — | Kieren Marr Co-Founder | Series B | — | — |
| 4 | ILiAD Biotechnologies Developer of immunity-inducing vaccine for the prevention and treatment of pertussis 24Funding top 25%Moat top 36%Patents top 38%Innovation top 42% All 9 signals ▾Fundingtop 25% Moattop 36% Patentstop 38% Innovationtop 42% Newsbottom 49% Talentbottom 49% Globalbottom 36% Marketbottom 24% Techbottom 22% Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $51M | 7 mo ago | 8 | Keith Rubin Founder & CEO | Series B | 24 patents Lyophilized live bacterial vaccine production and neuroprotective therapeutic formulations. | — |
| 5 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 15 mo ago | 6 | Jeffrey Meckler Chief Executive Officer | Public | — | — |
| 6 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 24 mo ago | 10 10 → 8 (-20%) | David Ho Co-Founder | Series A | 11 patents Nucleic acid delivery devices and plasmid expression vectors for therapeutic proteins | — |
| 7 | Varro Life Sciences Developer of a technology to detect infectious agents in breath and air | $20M | 22 mo ago | — | Tom Cirrito Co-Founder & CEO | Seed | — | — |
| 8 | Lodo Therapeutics Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | $20M | 116 mo ago | 24 | Sean Brady Co-Founder | Acquired | — | — |
| 9 | Autonomous Therapeutics Developer of drugs for influenza & other infectious diseases treatment | $17M | 17 mo ago | 21 | Ariel Weinberger Co-Founder & CEO | Funding Raised | — | — |
| 10 | CastleVax Developer of vaccines to treat infectious diseases | $8M | 35 mo ago | — | Matthew Stober CEO | Funding Raised | — | — |
| 11 | Archean Biologics Developer of therapeutics for influenza | $4M | 63 mo ago | 6 | Christian Rudder Co-Founder | Deadpooled | — | — |
| 12 | Tonix Pharma Developer of next-generation medicines for CNS and immunological disorders | $4M | 17 mo ago | 117 117 → 169 (+44%) | — | Public | — | — |
| 13 | Exavir Developer of therapeutics for the treatment of viral diseases | $4M | 36 mo ago | 3 | Howard Gendelman Co-Founder | Seed | — | — |
| 14 | Helocyte Developing immunotherapies for cancer and infectious diseases, particularly cytomegalovirus | $4M | 118 mo ago | 2 | — | Funding Raised | — | — |
| 15 | Voltron Therapeutics Develoepr of therapeutics to treat covid-19 and cancer | $3M | 46 mo ago | — | Patrick Gallagher CEO | Series A | — | — |
| 16 | Arcturus Developer of messenger RNA medicines and vaccines for infectious diseases | $2M | 67 mo ago | 4 | Ben Salander Co-Founder | Seed | 2 patents RNA cap analog synthesis and modular AI knowledge-base configuration | — |
| 17 | Mercia Pharma Vaccine in combination with adjuvants for autoimmune, CNS, respiratory and infectious diseases | $2M | 206 mo ago | — | Peter Blackburn President and Founder | Funding Raised | — | — |
| 18 | Reme-D.Inc Developer of diagnostic kits for both human and animal diseases 27Patents top 30%Global top 38%Innovation top 41%Funding top 44% All 7 signals ▾Patentstop 30% Globaltop 38% Innovationtop 41% Fundingtop 44% Talentbottom 49% Techbottom 30% Marketbottom 25% Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 5 mo ago | — | Salma Tammam Founder & CEO | Seed | 42 patents Advanced piston and fluid control valves for rotary steerable drilling tools | — |
| 19 | Symbiotic Health Develops microbiome-based therapeutics for gastrointestinal infection | $1M | 119 mo ago | 7 | Gerard Honig CEO and Founder | Deadpooled | — | — |
| 20 | Assembly Biosciences Developing novel antivirals to treat serious viral diseases | $700K | 20 mo ago | 169 169 → 99 (-41%) | Atul Kumar Founder & Managing Director | Public | 317 patents Antiviral heterocyclic small molecules and crystalline forms for herpes virus treatment | — |
| 21 | Epitor Therapeutics Developer of therapeutics based on gene editing technologies | $698K | 23 mo ago | — | Megan McGill CEO | Funding Raised | — | — |
| 22 | Ichor Biologics Developer of monoclonal antibodies for treating infectious and inflammatory diseases | $300K | 88 mo ago | 21 | Raymond Alvarez Co-Founder & CEO | Funding Raised | 6 patents Therapeutic monoclonal antibodies targeting Andes hantavirus for diagnosis and treatment | — |
| 23 | Lab11 Therapeutics Developer of anti-viral drugs to treat viral infections | $256K | 60 mo ago | 2 | — | Funding Raised | — | — |
| 24 | A2A Pharmaceuticals AI-driven pharmaceutical company developing novel drug alternatives for life-threatening diseases | $250K | 119 mo ago | 4 | Edward Painter Founder | Seed | — | — |
| 25 | Bioharmony Therapeutics Company developing lysin based therapeutics for treating infectious diseases caused by bacteria | $100K | 104 mo ago | 1 | Chandrabali Ghose Founder & CEO | Deadpooled | — | — |
| 26 | Apertura Gene Therapy Developer of gene therapies for the treatment of rare diseases | — | 52 mo ago | 25 | Joseph La Barge Chief Executive Officer | Series A | — | — |
| 27 | Aevitas Therapeutics Developer of gene therapies to treat ophthalmological and rare diseases | — | — | — | Markus Peters CEO | Deadpooled | — | — |
| 28 | Artemis Therapeutics Online gaming platform offering slots, casino, sports, and arcade games | — | — | 4 | — | Unfunded | — | — |
Top 12 Infectious Diseases companies in New York City
#1
Series B · New York City, New York · founded 2012 · 8 employees$51.2Mraised▾
Developer of immunity-inducing vaccine for the prevention and treatment of pertussis. Its lead candidate BPZE1, a live attenuated Bordetella pertussis (BP) vaccine claims to induce sterilizing mucosal immunity and long-lasting protection against pertussis disease. The candidate is nasally administered BPZE to induce both mucosal and systemic potent immune responses.
- Feb 2026Series B$115M
- Dec 2023Series A—
- Sep 2022Series A$42.8M
- May 2022Grant (prize money)$972.1K
#2
Public · New York City, New York · founded 2021 · 6 employees$37.9Mraised▾
Developer of immunotherapies for oncology and infectious diseases. The lead candidate Decoy20 provides broad anti-tumor and anti-viral responses in combination for the treatment of colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin’s lymphoma.
- Jun 2025Post IPO$5.7M
- Jan 2025Post IPO$2.2M
- Jul 2021Post IPO$30M
#3
Seed · New York City, New York · founded 2022$1.5Mraised▾
Developer of diagnostic kits for both human and animal diseases. It offers kits for nucleic acid extraction, amplification, sequencing, and detection to diagnose both infectious and non-infectious diseases.
- Apr 2026Seed$500K
- Nov 2023Grant (prize money)$10K
- Seed$1M
#4
Funding Raised · New York City, New York · founded 2017 · 21 employees$16.8Mraised▾
Autonomous Therapeutics is a developer of drugs for influenza & other infectious diseases treatment. It has developed a therapeutic platform against infectious diseases and cancer.
- Apr 2025Grant (prize money)$6.4M
- May 2024Grant (prize money)$273.6K
- Apr 2020Grant (prize money)$5.7M
- Jun 2017Grant (prize money)$4.5M
#5
Public · New York City, New York · founded 2007 · 117 employees$4.5Mraised▾
Developer of next-generation medicines for CNS and immunological disorders. The lead product of the company is TNX-601 (tianeptine oxalate), for the treatment of Post-traumatic stress disorder (PTSD), and TNX-801 for horsepox virus.
- Apr 2025Grant (prize money)$5.2M
- Feb 2025Grant (prize money)$5.2M
- Oct 2022Post IPO$15M
- Aug 2022Grant (prize money)—
#6
Seed · New York City, New York · founded 2020$20Mraised▾
Developer of a technology to detect infectious agents in breath and air. It offers a biodetector devices that combines microbiology, aerosols engineering, and advanced electronics for real-time detection of respiratory pathogens.
- Oct 2024Angel$20M
#7
Series B · New York City, New York · founded 2024$81Mraised▾
Developer of therapeutics for invasive fungal infections. It offers a lead candidate SF001 for IV infusion which comprises a micellar solution of Sfu-AM2-19A, a polyene compound used for the treatment of aspergillosis.
- Jun 2024Series B$81M
#8
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
#9
Public · New York City, New York · founded 2017 · 395 employees$593Mraised▾
Developer of drugs for the treatment of cancer. The company has a portfolio of eight promising drug candidates for oncology, immunology, cardio-renal disease, and infectious disease. The company is developing kinase inhibitors that include FGF401 which is a fibroblast growth factor receptor 4 kinase inhibitor used to treat cancer.
- Jun 2020Series C$260M
- Mar 2020Series C$50M
- 2018Series A$3M
#10
Public · New York City, New York · founded 1995 · 39 employees$247.7Mraised▾
Developer of anti-infective therapeutics for bio-warfare threats. It offers a lead candidate, TPOXX (tecovirimat), which blocks the ability of the virus to spread, thus preventing disease symptoms in animal models of smallpox.
- Nov 2016Conventional Debt$115M
- Jul 2013Grant (prize money)$5.8M
- Aug 2011Grant (prize money)$7.7M
- Aug 2011Grant (prize money)$7.1M
#11
Public · New York City, New York · founded 2005 · 169 employees$700Kraised▾
Developing novel antivirals to treat serious viral diseases. The company is a biopharmaceutical organization focused on discovering and developing innovative antiviral therapeutics. Their pipeline includes programs targeting herpesviruses, hepatitis delta virus (HDV), and hepatitis B virus (HBV). They leverage expertise in virology to advance treatment options for individuals facing the burden of chronic viral infections. The company is dedicated to research and development, aiming to change the treatment paradigm for viral infections. They are passionate, purpose-driven, and patient-focused, committed to improving the lives of people facing serious viral diseases through novel antiviral solutions.
- Dec 2024Post IPO$20.1M
- Jun 2024Post IPO—
- May 2010Seed$700K
#12
Funding Raised · New York City, New York · founded 2023$698.5Kraised▾
Developer of therapeutics based on gene editing technologies. It offers technology using CRISPR-Cas to target specific genes and modulate gene expression without editing the underlying DNA, offering innovative therapies for various diseases. The company offers CasNano, a CRISPR-Cas system for single AAV therapies for developing gene and cell therapy.
- Sep 2024Grant (prize money)$698.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
How research on Diagnostics is moving in the United States
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,526 United States-affiliated papers.
- Harvard University330
- Johns Hopkins University318
- Heidelberg University249
- Massachusetts General Hospital214
- The University of Texas MD Anderson Cancer Center191
- Liquid biopsy125→427
- Biopsy15→114
- Biomarker17→103
- Point-of-care testing112→195
- Cancer67→146
- Liquid biopsy183→739
- Biopsy42→285
- Biomarker55→208
- Cancer115→260
- Oncology57→183
- Liquid biopsy67→239
- Biopsy17→99
- Biomarker28→86
- Coronavirus disease 2019 (COVID-19)1→44
- Cancer55→92
Where diagnostics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing diagnostics patents in the United States
United States diagnostics patent filing is accelerating — 418 filings from 196 assignees (2016–2025), led by Detect, UNIV Leland Stanford Junior, Washington University ST Louis; annual filings 13→55.
- Detect42
- UNIV Leland Stanford Junior33
- Washington University ST Louis20
- Nuclein19
- UNIV California19
- Texas A & M UNIV SYS19
- New England Biolabs18
- Tempus LABS18
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.